MetaCap

Jupiter Neurosciences (JUNS) vs Propanc Biopharma (PPCB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Propanc Biopharma is the larger company by market cap ($1.9 million vs $1.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JUNS-56.51%PPCB+256.93%
+409%+165%-79%
Oct 7, 20261 yearNov 20, 2026
JUNS-56.67%PPCB+266.48%
+317%+121%-74%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JUNS versus PPCB key metrics
MetricJUNSPPCB
Share price$1.24$1.78
Market cap$1.63M$1.87M
1-day change-18.75%+3.19%
Forward P/E20.58—
EPS (TTM)$-22.53$-95.92
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$21.80K—
Net income (latest FY)$-8.64M$-18.86M
Gross margin80.59%—
Operating margin-40873.19%—
Net margin-39662.77%—
52-week high$97.73$315.00
52-week low$1.20$1.61
Distance from 52-week high-98.74%-99.43%
Average volume69.86K188.66K
Shares outstanding1.32M1.05M
Employees52
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Jupiter Neurosciences

JUNS stock →

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Propanc Biopharma

PPCB stock →

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

JUNS vs PPCB FAQ

Which is bigger, Jupiter Neurosciences or Propanc Biopharma?

Propanc Biopharma (PPCB) is larger, with a market capitalization of $1.87M compared with $1.63M for Jupiter Neurosciences (JUNS).

Are Jupiter Neurosciences and Propanc Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons